Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 366 of the 366 references it cites were found in a registry or an index.

MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women

Open access

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease influenced by genetic, lifestyle, and environmental factors. While MASLD is more prevalent in men, women are at increased risk after menopause, highlighting the critical pathogenetic role of sex hormones. The complex interplay between estrogen deficiency, visceral fat accumulation, metabolic syndrome (MetS), and inflammation accelerates disease progression, increases cardiovascular (CV) risk, and triggers a cycle of worsening adiposity, metabolic dysfunction, and psychological problems, including eating disorders. Weight loss in postmenopausal women can significantly improve both metabolic and psychological outcomes, helping to prevent MASLD and related conditions. This review examines the prevalence of MASLD, its comorbidities (type 2 diabetes T2D, CV, mental disorders), pathogenetic mechanisms, and pharmacological treatment with GLP-1 receptor agonists (GLP1-RAs), with a focus on postmenopausal women. Given the use of GLP1-RAs in the treatment of obesity and T2D in MASLD patients, and the increase in MetS and MASLD after menopause, this review analyzes the potential of a stable GLP-1–estrogen conjugate as a therapeutic approach in this subgroup. By combining the synergistic effects of both hormones, this dual agonist has been shown to increase food intake and food reward suppression, resulting in greater weight loss and improved insulin sensitivity, glucose, and lipid metabolism. Therefore, we hypothesize that this pharmacotherapy may provide more targeted therapeutic benefits than either hormone alone by protecting the liver, β-cells, and overall metabolic health. As these effects are only supported by preclinical data, this review highlights the critical need for future research to evaluate and confirm the mechanisms and efficacy in clinical settings, particularly in postmenopausal women.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines13040855

Cites

366 of 366 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 MASLD development and progression after menopause: the interplay between hormonal changes, weight gain, metabolic dysfunction, genetics, and mental health disorders. SAT: subcutaneous adipose tissue; FFAs: free fatty acids; VAT: visceral adipose tissue; HSCs: hepatic stellate cells; MASLD: metabolic dysfunction-associated steatotic liver disease; MASH: metabolic dysfunction-associated steatohepatitis; HCC: hepatocellular carcinoma.
Figure 1 MASLD development and progression after menopause: the interplay between hormonal changes, weight gain, metabolic dysfunction, genetics, and mental health disorders. SAT: subcutaneous adipose tissue; FFAs: free fatty acids; VAT: visceral adipose tissue; HSCs: hepatic stellate cells; MASLD: metabolic dysfunction-associated steatotic liver disease; MASH: metabolic dysfunction-associated steatohepatitis; HCC: hepatocellular carcinoma.CC BY · PubMed Central
Figure 2 Stable GLP-1–estrogen conjugate as a promising therapeutic strategy for MASLD and its hepatic and extrahepatic comorbidities (T2D, CV diseases, MetS, mental disorders). Glp-1: glucagon-like peptide 1; GLP1-R: glucagon-like peptide 1 receptor; ER-alpha: estrogen receptor alpha; PVN: paraventricular nucleus; LHA: lateral hypothalamic area; ARC: arcuate nucleus; MeA: medial amygdala; VTA: ventral tegmental area; NTS: nucleus of the solitary tract; DRN: dorsal raphe nucleus; SUM: supramammillary nucleus; MASLD: metabolic dysfunction-associated steatotic liver disease; MASH: metabolic dysfunction-associated steatohepatitis; HCC: hepatocellular carcinoma.
Figure 2 Stable GLP-1–estrogen conjugate as a promising therapeutic strategy for MASLD and its hepatic and extrahepatic comorbidities (T2D, CV diseases, MetS, mental disorders). Glp-1: glucagon-like peptide 1; GLP1-R: glucagon-like peptide 1 receptor; ER-alpha: estrogen receptor alpha; PVN: paraventricular nucleus; LHA: lateral hypothalamic area; ARC: arcuate nucleus; MeA: medial amygdala; VTA: ventral tegmental area; NTS: nucleus of the solitary tract; DRN: dorsal raphe nucleus; SUM: supramammillary nucleus; MASLD: metabolic dysfunction-associated steatotic liver disease; MASH: metabolic dysfunction-associated steatohepatitis; HCC: hepatocellular carcinoma.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 366 references

Cited by

See all 39

Metadata

Authors
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D.
Affiliations
Sapienza University of Rome (IT)
Corresponding author
Milani, Ilaria
Venue
Biomedicines
Publisher
MDPI AG
Published
2025-04-02
Volume
13
Issue
4
Pages
855
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4409101902
Cited by
38
References
366
Citations by year
2026: 28 · 2025: 10
FWCI
5.84
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
non-alcoholic fatty liver disease, postmenopausal women, sex hormones, estrogen deficiency, GLP-1 receptor agonists, weight loss, metabolic syndrome, visceral fat, type 2 diabetes, cardiovascular risk, insulin sensitivity, eating disorders, liver disease comorbidity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women. https://app.cochat.ai/papers/10.3390/biomedicines13040855
The paper
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025). MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women. Biomedicines. https://doi.org/10.3390/biomedicines13040855

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.